Early cancer trial success for E-Therapeutics
Drug discovery company E-Therapeutics? (ETX: AIM) latest update has been warmly received by the market. The £90 million cap improved by 14.2% to 34.25p after announcing positive progress in Phase I clinical trials of its cancer...
14 May 2013
